Apollomics completes enrollment in phase 3 bridging study of uproleselan in chinese patients with relapsed/refractory acute myeloid leukemia

Foster city, calif., jan. 03, 2024 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics” or the “company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollment in its phase 3 bridging study evaluating uproleselan (apl-106), an investigational, first-in-class e-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia (relapsed/refractory aml).
APLM Ratings Summary
APLM Quant Ranking